Ozark Health Ventures, LLC dba Cancer Research for the Ozarks

Ozark Health Ventures, LLC dba 奥扎克癌症研究

• 批准号: 8851770
• 负责人: Jay W Carlson
• 金额: $ 3.57万
• 依托单位: OZARK HEALTH VENTURES, LLC
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-08-15 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8851770
• 关键词: African American; Area; Asian Americans; Awareness; Cancer Control; Cancer Prevention Trial; Cancer Research Project; Clinical Trials; Commit; Communities; Community Clinical Oncology Program; Controlled Study; Data; Development; Enrollment; Event; Feedback; Future; Goals; Grant; Health; Health system; Healthcare Systems; Hispanics; Individual; Instruction; Leadership; Malignant Neoplasms; Marketing; Minority; Minority Groups; Mission; Missouri; Monitor; Native Americans; Nursing Administration Research; Nursing Research; Oncologist; Ozarks; Participant; Patient Participation; Patients; Physicians; Population; Prevention; Primary Health Care; Protocols documentation; Qualifying; Quality of Care; Radiation Oncologist; Recommendation; Recruitment Activity; Registered nurse; Reporting; Research; Research Personnel; Resources; Rural Community; Schedule; Screening for cancer; Site; Specialist; Surgeon; Team Nursing; Testing; Time; Training; Urologist; Validity and Reliability; anticancer research; base; cancer care; cancer therapy; control trial; meetings; member; oncology; prevent; programs; quality assurance; screening; symposium; therapy development; treatment trial

For over 20 years, Cancer Research for the Ozarks (CRO) has provided NCI-approved clinical trials to the rural communities of Southwestern Missouri and surrounding areas. Through the visionary leadership of physicians Wendall Goodwin, MD and Robert L. Carolla, MD, patients who otherwise would not have access to clinical trials can elect to participate through the Community Clinical Oncology Program. From its inception, CRO has had the support of the two nationally recognized health care systems, CoxHealth and St. John's Health System in Springfield, Missouri. With the later addition of two Joplin affiliates, CRO now provides more than 95 percent of cancer care resources in the area including a physician network of oncologists, radiation oncologists, gynecological oncologists, urologists, surgeons, and primary care specialists. CRO supports the CCOP mission of accelerating development of interventions to prevent and treat cancer by increasing accruals to trials. CRO exceeds five percent patient participation with over 200 patients enrolled to treatment and prevention and control trials each of the past five years. CRO's thirty-three physician investigators actively participate in the program increasing awareness of recent developments in treatment, control and prevention and the overall quality of care in the community. CRO has also successfully increased involvement of minorities enrolling a higher percentage than that of the general cancer population. RELEVANCE (See instructions!: Research is the future of mankind. Cancer Research for the Ozarks offers NCI oncology treatment along with cancer control and prevention trials to Springfield and the surrounding communities. The ultimate goal of participation is to find the cure for cancer.

20多年来，欧扎克癌症研究中心(CRO)提供了NCI批准的临床试验 到密苏里州西南部及周边地区的农村社区。通过梦想家 医生温德尔·古德温(医学博士)和罗伯特·L·卡罗拉(医学博士)的领导力，患者 将无法获得临床试验的人可以选择通过社区临床参与 肿瘤学课程。 从一开始，CRO就得到了两个国家公认的医疗保健系统的支持， 密苏里州斯普林菲尔德的CoxHealth和圣约翰健康系统。后来又增加了两个 乔普林附属公司，CRO现在提供该地区95%以上的癌症护理资源 包括肿瘤学家、放射肿瘤学家、妇科肿瘤学家、 泌尿科医生、外科医生和初级保健专家。 CRO支持CCOP加快制定预防和治疗干预措施的使命 通过增加试验的应计费用来治疗癌症。CRO超过5%的患者参与率超过200 在过去五年中，每年都有患者登记参加治疗和预防控制试验。 CRO的33名内科调查人员积极参与该计划，提高人们的认识 在治疗、控制和预防方面的最新发展以及儿童的整体护理质量 社区。CRO还成功地增加了少数族裔的参与， 这一比例高于普通癌症人群。 相关性(参见说明！)： 研究是人类的未来。Ozarks癌症研究中心为NCI提供肿瘤治疗 将癌症控制和预防试验带到斯普林菲尔德和周围社区。终极目标 参与的关键是找到治疗癌症的方法。

项目成果

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

• DOI: 10.1016/j.ygyno.2018.05.018
• 发表时间: 2018-08
• 期刊: Gynecologic oncology
• 影响因子: 4.7
• 作者: Aghajanian C;Filiaci V;Dizon DS;Carlson JW;Powell MA;Secord AA;Tewari KS;Bender DP;O'Malley DM;Stuckey A;Gao J;Dao F;Soslow RA;Lankes HA;Moore K;Levine DA
• 通讯作者: Levine DA